Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Clinical manifestations, management, and outcomes in patients with triple positive antiphospholipid antibodies

Madeline Young, Maria T DeSancho Nov 03, 2025 pp. 4890-4890 10.1182/blood-2025-4890

Abstract Introduction Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, or microvascular thrombos...

Construction and validation of a prediction model for extracorporeal circuit clotting risk during regional citrate anticoagulation in continuous renal replacement therapy for critically ill patients with hematological disorders

Jian Zhang, Xiaoying Wang, Jianxiong Hong et al. Nov 03, 2025 pp. 6166-6166 10.1182/blood-2025-6166

Abstract Background: Continuous renal replacement therapy (CRRT) is increasingly employed for critically-ill patients with hematologic disor...

Immune dysregulation in newly diagnosed DLBCL: From clinical observations to molecular mechanisms

Ruixin Zheng, Yuanyuan Pan, Bing Pan et al. Nov 03, 2025 pp. 7085-7085 10.1182/blood-2025-7085

Abstract Background: Diffuse large B-cell Lymphoma (DLBCL) is an aggressive malignancy where the tumor immune microenvironment (TME) plays a...

Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data

Evan Chen, Xiaoqin Yang, Mavis Obeng-Kusi et al. Nov 03, 2025 pp. 2837-2837 10.1182/blood-2025-2837

Abstract Background: Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by sustained thrombocytosis...

Single-nucleus dissection of peripheral T-cell lymphomas reveals distinct microenvironmental ecosystems and therapeutic vulnerabilities

Wen-Hsuan Wendy Lin, Anqi Wang, Jean-Baptiste Reynier et al. Nov 03, 2025 pp. 1787-1787 10.1182/blood-2025-1787

Abstract Peripheral T-cell lymphomas (PTCL) are aggressive hematologic cancers characterized by complex tumor microenvironments (TME) with r...

IVIG successfully halts a recurrent hyperhaemolysis syndrome in a young patient with sickle cell crisis

Archa Rajesh, Anbar Ahmad, Taha Ahmed et al. Nov 03, 2025 pp. 6516-6516 10.1182/blood-2025-6516

Abstract Hyperhaemolysis syndrome is a rare blood transfusion complication putting patients requiring repeat transfusions frequently at risk...

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Danyang Li, Rui Liu, Zhonghua Fu et al. Nov 03, 2025 pp. 672-672 10.1182/blood-2025-672

Abstract Background: CD19-directed chimerical antigen receptor T-cell (CAR-T) therapy as an immunotherapy has documented significant clinica...

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

Yi Zhu, Xiwen Tong, Bin Xu et al. Nov 03, 2025 pp. 6989-6989 10.1182/blood-2025-6989

Abstract Background: Patients with relapsed/refractory acute myeloid leukemia (R/R AML) face dismal outcomes, highlighting the critical need...

Defining clinical risks of venous thromboembolism in children with intestinal failure

Alayna Koch, Gillian Goddard, Jorie Gatts et al. Nov 03, 2025 pp. 4916-4916 10.1182/blood-2025-4916

Abstract Introduction Patients with intestinal failure are living longer as the rates of intestinal failure-associated liver disease (IFALD)...

Conserved residues in the GPIbα mechanosensory domain are important for its expression and signaling

Hua Huang, Zhiting Guo, Hongyan Tong et al. Nov 03, 2025 pp. 6575-6575 10.1182/blood-2025-6575

Abstract Background: Glycoprotein Ib-IX (GPIb-IX), the primary receptor for von Willebrand factor (VWF) on platelets, mediates initial plate...

Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study

Robert Zeiser, Annie Im, Albert Assad et al. Nov 03, 2025 pp. 6012-6012 10.1182/blood-2025-6012

Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and non-relapse mortality in patients who u...

Integrating thymic expression patterns into tumor antigen selection enhances immunotherapy design and stratifies clinical responses to immunotherapies

Adrienne Long, Kaitlyn Tooker, Nicholas Pathoulas et al. Nov 03, 2025 pp. 626-626 10.1182/blood-2025-626

Abstract Introduction: Tumor associated antigens (TAAs; non-mutated proteins overexpressed in cancer relative to healthy tissues) are promis...

Degradation of IgG autoantibodies associated with platelet disorders by a half-life extended IgG protease

Emily Frazier, Benjamin Dutzar, Maximilian Sauer et al. Nov 03, 2025 pp. 417-417 10.1182/blood-2025-417

Abstract Multiple blood disorders are mediated by immunoglobulin G (IgG) autoantibodies that recognize self-antigens associated with platele...

Talquetamab outcomes from practice outside of clinical trials: The bital study

María-Victoria Mateos, Marcos Lorenzo Perez, Ana Saus Carreres et al. Nov 03, 2025 pp. 5827-5827 10.1182/blood-2025-5827

Abstract Introduction: Talquetamab (Tal) is the first bispecific antibody (BsAb) that targets the G protein-coupled receptor family C group...

Other cancers in patients with chronic lymphocytic leukemia/SMALL lymphocytic lymphoma

Helen Ma, Kari Rabe, Edward Ratner et al. Nov 03, 2025 pp. 4529-4529 10.1182/blood-2025-4529

Abstract Introduction: Patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) exhibit an elevated risk...

Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma.

Cristina Teresa Fuentes-Morales, Maria García-Alvarez, David Alonso Castronuño et al. Nov 03, 2025 pp. 3541-3541 10.1182/blood-2025-3541

Abstract INTRODUCTION: First-line treatment is curative in more than 80% of patients with Hodgkin lymphoma (HL). However, ~20% of cases relap...

FBXO7 通过靶向 TMED10 进行泛素介导的降解和激活 wnt 信号传导来促进 T-ALL 的化疗耐药性

zefan du, ouyang cheng, Chi Kong LI et al. Nov 03, 2025 pp. 3263-3263 10.1182/blood-2025-3263

Abstract Acute T-cell lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy derived from T-lineage progenitor cells, accoun...

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Howard Chang, Staci Williamson, Daniel Chandra et al. Nov 03, 2025 pp. 7744-7744 10.1182/blood-2025-7744

Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only curative treatment for many older adults...

AI-enhanced image analysis of point of care tests for sickle cell disease screening in Uganda – a pilot cluster randomized trial

Anne Akullo, Cosmas Wamoto, Deogratias Munube et al. Nov 03, 2025 pp. 2603-2603 10.1182/blood-2025-2603

Abstract Background: In Sub Sahara Africa (SSA) where the burden of Sickle cell disease (SCD) is highest, newborn screening for SCD is not w...

Genetic characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients with CRLF2 rearrangements

Grigory Tsaur, Ivan Kotov, Elena Chetverikova et al. Nov 03, 2025 pp. 6883-6883 10.1182/blood-2025-6883

Abstract Background. Acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements (CRLF2r) is one of the most common subtype of BCR::ABL1-li...

Beta thalassemia major and pregnancy outcomes: Evidence of severe transfusion burden and iron overload complications in a national cohort

Benedict Amalraj, Mariana Marrero Castillo, Shidestini Martinez et al. Nov 03, 2025 pp. 4692-4692 10.1182/blood-2025-4692

Abstract Introduction: Beta thalassemia major (Cooley's anemia) results from a severe reduction or absence of beta-globin chain synthesis, l...

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

Kai Shen, Chenlu Yang, Jinrong Yang et al. Nov 03, 2025 pp. 7433-7433 10.1182/blood-2025-7433

Abstract Introduction: Zanubrutinib as a second generation bruton tyrosin kinase inhibitor (BTKi) has become the standard of care for both f...

Preliminary analysis of the role of magnesium in transplant-associated thrombotic microangiopathy via complement activation pathways

Xiaofan Li, Chunxiao He Nov 03, 2025 pp. 1327-1327 10.1182/blood-2025-1327

Abstract Objective: This study aimed to retrospectively analyze the clinical features, potential risk factors, and prognosis of patients dia...

The safety and efficacy of pirtobrutinib in adults with immune thrombocytopenia: A phase 1/2 dose-finding study in progress

Catherine Broome, Tomas Jose Gonzalez-Lopez, Ananya Guntur et al. Nov 03, 2025 pp. 8231-8231 10.1182/blood-2025-8231

Abstract Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by reduced platelet counts and increased risk o...

The heights of iron absorption: Erythrocytosis in patients with heterozygous HFE mutations at altitude

Braden Olsen, Taylor Jones, Kaylee Dollerschell et al. Nov 03, 2025 pp. 6464-6464 10.1182/blood-2025-6464

Abstract Background: Hemochromatosis (HC) is a disorder characterized by increased iron absorption from the intestines a...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page